Literature DB >> 21840598

Nilotinib therapy does not induce consistent modifications of cholesterol metabolism resulting in clinical consequences.

Massimo Breccia, Giuseppina Loglisci, Laura Cannella, Alessandra Serrao, Gioia Colafigli, Adriano Salaroli, Giuliana Alimena.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21840598     DOI： 10.1016/j.leukres.2011.07.026

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  2 in total

1.  Statin-induced myopathy prevented by creatine administration.

Authors:  Maurizio Balestrino; Enrico Adriano
Journal:  BMJ Case Rep       Date:  2018-08-27

2.  The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model.

Authors:  Marianne G Pouwer; Elsbet J Pieterman; Lars Verschuren; Martien P M Caspers; Cornelis Kluft; Ricardo A Garcia; Jurjan Aman; J Wouter Jukema; Hans M G Princen
Journal:  Front Cardiovasc Med       Date:  2018-06-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.